相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antitumor Activity of BRAF Inhibitor Vemurafenib in Preclinical Models of BRAF-Mutant Colorectal Cancer
Hong Yang et al.
CANCER RESEARCH (2012)
Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment
Joost S. Vermaat et al.
CLINICAL CANCER RESEARCH (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
The American College of Gastroenterology Emily Couric Lecture-The Adenoma-Carcinoma Sequence Revisited: Has the Era of Genetic Tailoring Finally Arrived
Dennis J. Ahnen
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
N. Knijn et al.
BRITISH JOURNAL OF CANCER (2011)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Phosphorylated AKT Expression Is Associated With PIK3CA Mutation, Low Stage, and Favorable Outcome in 717 Colorectal Cancers
Yoshifumi Baba et al.
CANCER (2011)
Dynamics of cancer cell subpopulations in primary and metastatic colorectal tumors
Teodora Evgenieva Goranova et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue
Richard D. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Validation Study of a Quantitative Multigene Reverse Transcriptase-Polymerase Chain Reaction Assay for Assessment of Recurrence Risk in Patients With Stage II Colon Cancer
Richard G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer
Ramon Salazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
Gordon Hutchins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
Erin S. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer-A Study of CALGB 9581 and 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
Frank A. Sinicrope et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Clinical Practice Guidelines in Oncology
Al B. Benson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Biomarker Use in Colorectal Cancer Therapy
Robin K. Kelley et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2011)
Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study
Marlies J. E. Kempers et al.
LANCET ONCOLOGY (2011)
Concordance of Predictive Markers for EGFR Inhibitors in Primary Tumors and Metastases in Colorectal Cancer: A Review
Jara M. Baas et al.
ONCOLOGIST (2011)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
PTEN status in advanced colorectal cancer treated with cetuximab
F. V. Negri et al.
BRITISH JOURNAL OF CANCER (2010)
Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine
G. Smith et al.
BRITISH JOURNAL OF CANCER (2010)
Molecular Markers in the Treatment of Metastatic Colorectal Cancer
Peter M. Wilson et al.
CANCER JOURNAL (2010)
Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data
Cecilia Guastadisegni et al.
EUROPEAN JOURNAL OF CANCER (2010)
Microsatellite Instability in Colorectal Cancer
C. Richard Boland et al.
GASTROENTEROLOGY (2010)
The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer
Mercy Mvundura et al.
GENETICS IN MEDICINE (2010)
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Wendy De Roock et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Oropharyngeal Cancer, Human Papilloma Virus, and Clinical Trials
Danny Rischin
JOURNAL OF CLINICAL ONCOLOGY (2010)
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Alberto Bardelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Genotype to phenotype: Analyzing the effects of inherited mutations in colorectal cancer families
Christopher D. Heinen
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2010)
Immunohistochemistry as First-line Screening for Detecting Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome A 2-antibody Panel May be as Predictive as a 4-antibody Panel
Jinru Shia et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F. Perrone et al.
ANNALS OF ONCOLOGY (2009)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients
Youji He et al.
CLINICAL CANCER RESEARCH (2009)
Lymphocytic Reaction to Colorectal Cancer Is Associated with Longer Survival, Independent of Lymph Node Count, Microsatellite Instability, and CpG Island Methylator Phenotype
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2009)
Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis
Gaetan Des Guetz et al.
EUROPEAN JOURNAL OF CANCER (2009)
Deletions Removing the Last Exon of TACSTD1 Constitute a Distinct Class of Mutations Predisposing to Lynch Syndrome
Marietta E. Kovacs et al.
HUMAN MUTATION (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
Monica M. Bertagnolli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer
Shuji Ogino et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection
Antonio Jimeno et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3 ' exons of TACSTD1
Marjolijn J. L. Ligtenberg et al.
NATURE GENETICS (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Multi-Determinants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR-Targeted Monoclonal Antibodies in Colorectal Cancer
Andrea Sartore-Bianchi et al.
PLOS ONE (2009)
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
Minaxi Jhawer et al.
CANCER RESEARCH (2008)
A prospective, multicenter, population-based study of BRAF mutational analysis for lynch syndrome screening
[Anonymous]
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2008)
Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers
Ludovic Barault et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Feasibility of Screening for Lynch Syndrome Among Patients With Colorectal Cancer
Heather Hampel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
EGFR FISH in colorectal cancer:: what is the current reality?
Mauro Moroni et al.
LANCET ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population
J. Abubaker et al.
ONCOGENE (2008)
Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study
Richard Gray et al.
LANCET (2007)
The genomic landscapes of human breast and colorectal cancers
Laura D. Wood et al.
SCIENCE (2007)
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
M. Frattini et al.
BRITISH JOURNAL OF CANCER (2007)
PIK3CA mutation is predictive of poor survival in patients with colorectal cancer
Shunsuke Kato et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors
Rosa M. Xicola et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression
C. Oliveira et al.
ONCOGENE (2007)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Microsatellite instability and colorectal cancer prognosis
P Benatti et al.
CLINICAL CANCER RESEARCH (2005)
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma:: an immunohistochemical and chromogenic in situ hybridization study
J Shia et al.
MODERN PATHOLOGY (2005)
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer
WS Samowitz et al.
GASTROENTEROLOGY (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab
WL Ince et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
The prevalence of PIK3CA mutations in gastric and colon cancer
S Velho et al.
EUROPEAN JOURNAL OF CANCER (2005)
RRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes
E Domingo et al.
ONCOGENE (2005)
Screening for the Lynch syndrome (Hereditary nonpolyposis colorectal cancer).
H Hampel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
M Moroni et al.
LANCET ONCOLOGY (2005)
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency - Familial colorectal cancer type X
NM Lindor et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
KY Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma
H Nagahara et al.
CLINICAL CANCER RESEARCH (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Tumour-infiltrating lymphocytes in colorectal cancer with microsatellite instability are activated and cytotoxic
SM Phillips et al.
BRITISH JOURNAL OF SURGERY (2004)
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer
JM Carethers et al.
GASTROENTEROLOGY (2004)
American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer
AB Benson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Somatic mutations of EGFR in colorectal cancers and glioblastomas
TD Barber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer
GR Deng et al.
CLINICAL CANCER RESEARCH (2004)
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
C Oliveira et al.
HUMAN MOLECULAR GENETICS (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Phenotype of microsatellite unstable colorectal carcinomas - Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability
JK Greenson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines
XX Chen et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2002)
PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers
XP Zhou et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
PTEN gene mutations in colorectal cancers displaying microsatellite instability
KH Shin et al.
CANCER LETTERS (2001)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Effect of nifedipine in metastatic colon cancer with DNA mismatch repair gene defect
JL Yang et al.
LANCET (2001)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Synergistic efficacy of 3n-butyrate and 5-fluorouracil in human colorectal cancer xenografts via modulation of DNA synthesis
RA Bras-Gonçalves et al.
GASTROENTEROLOGY (2001)
Histopathological identification of colon cancer with microsatellite instability
J Alexander et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Involvement of PTEN mutations in the genetic pathways of colorectal cancerogenesis
G Guanti et al.
HUMAN MOLECULAR GENETICS (2000)
分享论文
